Literature DB >> 10943692

Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice.

A R Carta1, C R Gerfen, H Steiner.   

Abstract

Central effects of psychostimulants such as cocaine are predominantly mediated by dopamine receptors. We have used mice with a targeted deletion of the D3 dopamine receptor subtype to investigate the role of this receptor in the regulation of gene expression in striatal neurons and behavior by acute and repeated treatment with cocaine (25 mg/kg). In mice lacking D3 receptors, acute administration of cocaine has more pronounced stimulatory effects on c-fos and dynorphin expression in the dorsal and ventral striatum. The behavioral response to cocaine is also increased in these mice. These findings indicate that the D3 receptor plays an inhibitory role in the action of cocaine on behavior and gene regulation in the striatum.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943692     DOI: 10.1097/00001756-200008030-00012

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

1.  Dopamine D1 and D3 receptors are differentially involved in cue-elicited cocaine seeking.

Authors:  Liping Chen; Ming Xu
Journal:  J Neurochem       Date:  2010-04-28       Impact factor: 5.372

2.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

3.  Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens.

Authors:  Daniel F Manvich; Alyssa K Petko; Rachel C Branco; Stephanie L Foster; Kirsten A Porter-Stransky; Kristen A Stout; Amy H Newman; Gary W Miller; Carlos A Paladini; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2019-03-16       Impact factor: 7.853

4.  Increased vulnerability to cocaine in mice lacking dopamine D3 receptors.

Authors:  Rui Song; Hai-Ying Zhang; Xia Li; Guo-Hua Bi; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

5.  The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice.

Authors:  Wei-Li Chang; Mark A Geyer; Mahalah R Buell; Martin Weber; Neal R Swerdlow
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

6.  Activation of dopamine D3 receptors inhibits reward-related learning induced by cocaine.

Authors:  H Kong; W Kuang; S Li; M Xu
Journal:  Neuroscience       Date:  2010-12-16       Impact factor: 3.590

7.  Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.

Authors:  Robert K McNamara; Aaron Logue; Kevin Stanford; Ming Xu; Jianhua Zhang; Neil M Richtand
Journal:  Synapse       Date:  2006-10       Impact factor: 2.562

8.  Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.

Authors:  Brian C Nolan; Shinban Liu; Lindsey R Hammerslag; Timothy H C Cheung; Jeffrey Lenz; Robert H Mach; Robert R Luedtke; Janet L Neisewander
Journal:  Synapse       Date:  2013-07-17       Impact factor: 2.562

9.  Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.

Authors:  Melissa L Perreault; Dawn Graham; Sarah Scattolon; Yufang Wang; Henry Szechtman; Jane A Foster
Journal:  Psychopharmacology (Berl)       Date:  2007-07-10       Impact factor: 4.530

10.  Cocaine self-administration in dopamine D₃ receptor knockout mice.

Authors:  S Barak Caine; Morgane Thomsen; Andrew C Barrett; Gregory T Collins; Peter Grundt; Amy Hauck Newman; Paul Butler; Ming Xu
Journal:  Exp Clin Psychopharmacol       Date:  2012-08-06       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.